<DOC>
	<DOCNO>NCT01650376</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) investigational agent , olaparib , give combination carboplatin paclitaxel patient relapse ovarian cancer uterine cancer . Furthermore , investigator intend study safety tolerability study treatment , response treatment , time disease progression , overall survival .</brief_summary>
	<brief_title>Phase Ib Study Olaparib Plus Weekly Carboplatin Paclitaxel Relapsed Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Advanced ( stage III IV ) , histologically cytologically documented ovarian cancer serious uterine cancer patient relapse primary therapy platinum taxane . This include : Platinum sensitive : relapse least 6 month follow platinum treatment Platinum refractory : cancer grow platinum treatment Platinum resistant : recurrence within 6 month platinum treatment Must fail first line treatment ECOG performance status 02 Must able swallow retain oral medication Life expectancy great 16 week Must normal organ bone marrow function define follow : Hemoglobin ≥ 9.0 g/dL Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L White blood cell ( WBC ) &gt; 3 x 10^9/L Platelet count ≥ 100 10^9/L Total bilirubin ≤ 1.5 x institutional upper limit normal AST ( SGOT ) /ALT ( SGPT ) ≤ x institutional upper limit normal unless liver metastasis present case must ≤ 5 ULN Serum creatinine ≤ 1.5 x institutional upper limit normal ( ULN ) Any previous treatment PARP inhibitor , include olaparib Any systemic chemotherapy , radiotherapy ( except palliative reason ) , within 2 week last dose prior study treatment ( long period depend defined characteristic agent use ) Currently receive follow class inhibitor CYP3A4 : azole antifungal , macrolide antibiotic , protease inhibitor Second primary cancer except adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , solid tumor curatively treat evidence disease ≥ 5 year Symptomatic uncontrolled brain metastasis Major surgery within 2 week start study treatment Immunocompromised patient , e.g. , patient know serologically positive human immunodeficiency virus ( HIV ) Known active hepatic disease ( i.e . Hepatitis B C ) Uncontrolled seizure History allergic reaction attribute compound similar chemical biologic composition carboplatin paclitaxel</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Ovarian Neoplasms</keyword>
	<keyword>Cancer Ovary</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Uterine Neoplasms</keyword>
	<keyword>Cancer Uterus</keyword>
	<keyword>Uterine Cancer</keyword>
	<keyword>Olaparib</keyword>
	<keyword>AZD2281</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Relapsed</keyword>
</DOC>